🔎 Trials Near Me

Home › Burkitt-lymfoom › Hawaï

Burkitt-lymfoom klinische studies in Hawaï

5 studies voor Burkitt-lymfoom zoeken deelnemers op locaties in Hawaï.

Steden in Hawaï

Officiële studietekst (Engels)

A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

  • Kapiolani Medical Center for Women and Children, Honolulu
RekruterenFase 2
366 Days – 46 Years · Alle geslachten · Bijgewerkt 2 okt. 2026 · NCT06124157

Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia

  • Straub Clinic and Hospital, Honolulu
  • Kapiolani Medical Center for Women and Children, Honolulu
  • Pali Momi Medical Center, ‘Aiea
RekruterenFase 3
Leeftijden 18 tot 39 · Alle geslachten · Bijgewerkt 2 okt. 2026 · NCT03150693

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

  • Kapiolani Medical Center for Women and Children, Honolulu
RekruterenFase 2
365 Days · Alle geslachten · Bijgewerkt 25 sep. 2026 · NCT06317662

A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

  • Kapiolani Medical Center for Women and Children, Honolulu
RekruterenFase 2
Leeftijden 1 tot 30 · Alle geslachten · Bijgewerkt 1 sep. 2026 · NCT04546399

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

  • Kapiolani Medical Center for Women and Children, Honolulu
RekruterenFase 3
365 Days – 25 Years · Alle geslachten · Bijgewerkt 25 aug. 2026 · NCT03959085

Van ClinicalTrials.gov, gegevens opgehaald op 5 okt. 2026. Elke studie stelt eigen deelnamecriteria vast; het studieteam bepaalt wie er kan deelnemen.